A 58-year-old Indian man with metastatic renal cell carcinoma (clear-cell type) is initiated on sunitinib, a multi-targeted tyrosine kinase inhibitor. After 2 weeks of therapy, he develops severe hypertension (BP 165/105 mmHg), and after 6 weeks, he complains of hand-foot skin reaction with painful erythema and blistering on his palms and soles. Which of the following best explains the mechanism underlying the hand-foot skin reaction?